

O I P E
JAN 14
FEB 08 2002
PATENT & TRADEMARK OFFICE

File 697

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	09/972,756
				Filing Date	October 05, 2001
				First Named Inventor	Katze et al.
				Group Art Unit	1636
				Examiner Name	J. Ketter
Sheet	1	of	4	Attorney Docket Number	A-70383-2/RMS/AXG

[illegible][illegible]

Examiner Signature	<i>Mr. T. V. A.</i>	Date Considered	<i>9/27/03</i>
-----------------------	---------------------	--------------------	----------------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

8085 1449A.FRM (1/01)

1071930

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/972,756
				Filing Date	October 05, 2001
				First Named Inventor	Katze et al.
				Group Art Unit	1636
				Examiner Name	J. Ketter
Sheet	2	of	4	Attorney Docket Number	A-70383-2/RMS/AXG

RECEIVED

FEB 13 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WV	3	Branch, A.D. "A good antisense molecule is hard to find," TIBS, 23:45-50 (1998).	
WV	4	Gura, T. "Systems for identifying new drugs are often faulty," Science, 278:1041-1042 (1997).	
WV	5	Alter, 1995, "Epidemiology of hepatitis C in the West," Semin. Liver dis. 15(1): 5-14.	
WV	6	Baber et al., 1994, "The 58-kilodalton inhibitor of the interferon-induced double-stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with oncogenic properties," Proc. Natl. Acad. Sci. USA 91(10): 4278-82.	
WV	7	Beattie et al., 1991, "Vaccina virus-encoded eIF-2 α homolog abrogates the antiviral effect of interferon," Virology 183:419-422.	
WV	8	Beattie et al., 1995, "Distinct pattern of IFN sensitivity observed in cells infected with Vaccina K3L and E3L mutant viruses," Virology 210:254-263.	
WV	9	Bukh et al., 1995, "Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes," Semin. Liver Dis. 15(1): 41-63.	
WV	10	Carroll et al., 1993, "Recombinant vaccina virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 α -specific protein kinase," J. Biol. Chem. 26: 12837-12842.	
WV	11	Craig et al., 1996, "The kinase insert domain of interferon-induced protein kinase PKR is required for activity but not for interaction with the pseudosubstrate K3L," J. Biol. Chem. 271(40): 24526-33.	
WV	12	Cuthbert, 1994, "Hepatitis C: progress and problems," Clin. Microbiol. Rev. 7(4): 505-32.	
WV	13	Davidson et al., 1995, "Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region," J. Gen. Virol. 76(Pt. 5):1197-204.	
WV	14	Dever et al., 1993, "Mammalian eukaryotic initiation factor 2 α kinases functionally substitute for GCN2 protein kinase in the GCN4 translational control mechanism of yeast," Proc. Natl. Acad. Sci. USA 90:4616-4620.	
WV	15	Di Bisceglie, 1995, "Hepatitis C and hepatocellular carcinoma," Semin. Liver Dis. 15(1):64-9.	
WV	16	Enomoto et al., 1995, "Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. sensitivity to interferon is conferred by amino acid substitution in the NS5A region," J. Clin. Invest. 96(1): 224-30.	
WV	17	Enomoto et al., 1996, "Mutation in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection," N. Engl. J. Med. 334(2):77-81.	
WV	18	Fields and Song, 1989, "A novel genetic system to detect protein-protein interactions. Nature, 340(6230): 245-6.	
WV	19	Fried et al., 1995, "Therapy of hepatitis C," Semin. Liver Dis. 15(1): 82-91.	
WV	20	Gale Jr. et al., 1996, "Interaction of the interferon-induced PKR proteins kinase with inhibitory proteins P58 ^{IPK} and Vaccina virus K3L is mediated by unique domains: implications for kinase regulation," Mol. Cell. Biol. 16:4172-4181.	

Examiner Signature	<i>W. T. Vozel</i>	Date Considered	9/23/03
--------------------	--------------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1071930

Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/972,756
				Filing Date	October 05, 2001
				First Named Inventor	Katze et al.
				Group Art Unit	1636
				Examiner Name	J. Ketter
Sheet 3 of 4	Attorney Docket Number A-70383-2/RMS/AXG				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>JK</i>	21	Gale et al., 1997, "Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein," Virology 230(2): 217-27.	
<i>JK</i>	22	Germandis et al., 1997, "Is there an interferon sensitivity determining region (ISDR) in the NS5A gene of hepatitis C virus," J. Hepatol. 26:93 (abstract P/C01/66).	
<i>JK</i>	23	Hoofnagle, 1994, "Therapy of acute and chronic viral hepatitis," Adv. intern. Med. 39:241-75.	
<i>JK</i>	24	Hu et al., 1990, "Sequence requirements for coiled-coils: analysis with lambda repressor-GCN4 leucine zipper fusions," Science 250 (4986): 1400-3.	
<i>JK</i>	25	Hu, 1995, "Repressor fusions as a tool to study protein-protein interactions," Structure 3(5): 431-3.	
<i>JK</i>	26	Kato et al., 1990, "Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis," Proc. Natl. Acad. Sci. USA 87(24): 9524-8.	
<i>JK</i>	27	Katze et al., 1987, "Adenovirus VAI RNA complexes with the 68,000 Mr protein kinase to regulate its autophosphorylation and activity," EMBO J. 6:689-697.	
<i>JK</i>	28	Katze et al., 1991, "Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated, 68,000-Mr protein kinase in a cell-free system," Mol. Cell. Biol. 11(11):5497-505.	
<i>JK</i>	29	Kumar et al., 1988, "Studies on the role of the 2'-5'-oligoadenylate synthetase-Rnase L pathway in beta interferon-mediated inhibition of encephalomyocarditis virus replication," J. Virol. 62:3175-3181.	
<i>JK</i>	30	Lee et al., 1994, "The 58,000-dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of protein," Mol. Cell. Biol. 14:2331-2342.	
<i>JK</i>	31	Lee et al., 1990, "Purification and partial characterization of a of a cellular inhibitor of the interferon-induced protein kinase of Mr 68,000 from influenza virus-infected cells," Proc. Natl. Acad. Sci. USA 87:6208-6212.	
<i>JK</i>	32	Mansell and Locarnini, 1995, "Epidemiology of hepatitis C in the East", Semin. Liver Dis. 15(1):15-32.	
<i>JK</i>	33	McMillan et al., 1995, "HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR," Virology 213: 413-424.	
<i>JK</i>	34	Meurs et al., 1990, "Molecular cloning and characterization of the human double -stranded RNA-activated protein kinase induced by interferon," Cell 62:379-390.	
<i>JK</i>	35	Okamoto et al., 1992, "Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources," J. Gen. Virol. 73 (Pt. 3): 673-9.	
<i>JK</i>	36	Romano et al., 1995, "Structured requirements for double-stranded RNA binding, dimerization, and activation of the human eIF-2α kinase DAI in Saccharomyces cerevisiae," Mol. Cell. Biol. 15:365-378.	
<i>JK</i>	37	Sen and Ransohoff, 1993, "Interferon-induced antiviral actions and their regulation," Adv. Virus Res. 42:57-107.	

Examiner Signature	<i>JK</i>	Date Considered	9/23/01
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



[illegible]

RECEIVED

FEB 13 2002

TECH CENTER 1600/2900

Examiner Signature	<i>Am. T. Noel</i>	Date Considered	9/23/03
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**